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AbstrAct
Objectives To establish a unique sample of proarrhythmia 
cases, determine the characteristics of cases and estimate 
the contribution of individual drugs to the incidence of 
proarrhythmia within these cases.
setting Suspected proarrhythmia cases were referred 
by cardiologists across England between 2003 and 2011. 
Information on demography, symptoms, prior medical and 
drug histories and data from hospital notes were collected.
Participants Two expert cardiologists reviewed data 
for 293 referred cases: 130 were included. Inclusion 
criteria were new onset or exacerbation of pre-existing 
ventricular arrhythmias, QTc >500 ms, QTc >450 ms 
(men) or >470 ms (women) with cardiac syncope, all 
secondary to drug administration. Exclusion criteria were 
acute ischaemia and ischaemic polymorphic ventricular 
tachycardia at presentation, structural heart disease, 
consent withdrawn or deceased prior to study. Descriptive 
analysis of Caucasian cases (95% of included cases, 
n=124) and culpable drug exposures was performed.
results Of the 124 Caucasian cases, 95 (77%) were QTc 
interval prolongation-related; mean age was 62 years (SD 
15), and 63% were female. Cardiovascular comorbidities 
included hypertension (53%) and patient-reported ‘heart 
rhythm problems’ (73%). Family history of sudden death 
(36%) and hypokalaemia at presentation (27%) were 
common. 165 culpable drug exposures were reported, 
including antiarrhythmics (42%), of which amiodarone and 
flecainide were the most common. Sotalol, a beta-blocking 
agent with antiarrhythmic activity, was also common 
(15%). 26% reported multiple drugs, of which 84% 
reported at least one cytochrome (CYP) P450 inhibitor. 
Potential pharmacodynamics interactions identified were 
mainly QT prolongation (59%).
conclusions Antiarrhythmics, non-cardiac drugs and 
drug combinations were found to be culpable in a large 
cohort of 124 clinically validated proarrhythmia cases. 
Potential clinical factors that may warn the prescriber of 
potential proarrhythmia include older women, underlying 
cardiovascular comorbidity, family history of sudden death 
and hypokalaemia.
IntrOductIOn
Drug-induced arrhythmia, or proarrhythmia, 
is the induction or exacerbation of cardiac 
arrhythmia associated with administration 
of a drug. The majority of drug-induced 
arrhythmic events relate to marked prolon-
gation of the QT interval of the ECG, which 
can lead to the distinctive polymorphic 
ventricular tachycardia (VT) and ‘Torsades 
de Pointes’ (TdP), which in turn may lead 
to ventricular fibrillation (VF) and sudden 
death.1 This is also known as the acquired 
long QT syndrome (aLQTS). Occasionally 
polymorphic and monomorphic VT without 
QT prolongation can occur.2 3 In addition to 
drugs, other causes of aLQTS include endo-
crine disorders,4 cirrhosis,5 HIV and AIDS,6 
inflammation and immunity,7 autoimmune 
disease,8 structural heart disease,9 electrolyte 
imbalances10 and eating disorders.11 
Drug-induced arrhythmia is associated 
with the use of cardiovascular agents (partic-
ularly class III antiarrhythmic drugs) and 
also with many non-cardiovascular indicated 
drugs within different therapeutic cate-
gories, including antihistamines, antipsy-
chotics and antimicrobials; an up-to-date list 
is maintained on the CredibleMeds register 
(Azcert, https:// crediblemeds. org/). 
Currently, there is substantial evidence to 
support a clear association between over 
50 different drugs and risk of TdP, even 
when taken according to the terms of the 
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Research
strengths and limitations of this study
 ► The Drug-induced Arrhythmia Risk Evaluation study 
has allowed the development of a cohort of cases of 
proarrhythmia.
 ► These cases have provided crucial safety 
information, as well as underlying clinical and 
genetic data.
 ► Only patients who did not die as a result of the 
proarrhythmia could be included.
 ► Referral of cases by cardiologists alone may have 
led to the underestimation of the prevalence of drug-
induced arrhythmia from non-cardiac drugs.
 ► The analysis of ethnicity and differences in risk of QT 
prolongation could not be investigated.
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marketing authorisation, with a number of these being 
withdrawn from the market.12–14 Mechanistic proposals 
for clinical features such as electrolyte imbalance include 
block of the rapid form of the delayed rectifier potas-
sium current (IKr) in cardiomyocytes.
15–17 Genetic factors 
have also been identified. These include single nucleo-
tide polymorphisms in the NOS1AP gene encoding the 
nitric oxide synthase 1 adaptor protein18; and mutations 
in potassium channel genes KCNH2, KCNQ1, KCNE1 and 
KCNE2 and/or the sodium channel gene SCN5A.19 20 
Such mutations are also recognised to cause congenital 
long QT syndrome (cLQTS).21 Other notable risk factors 
include female sex, bradycardia, recent cardioversion, 
pre-existing electrolyte disturbance, elevated plasma 
concentrations and/or rapid infusion of QT-prolonging 
drugs and digitalis toxicity.22–24
Following the removal of several QT-prolonging drugs 
because of associated sudden deaths,25–28 risk minimisa-
tion strategies were introduced to mitigate the arrhythmic 
risk posed by drugs, including clinical studies to assess the 
proarrhythmic potential for a new drug within the premar-
keting development programme.29 However it has been 
recognised that there remain limitations in the conduct 
of clinical studies designed to evaluate a drug’s potential 
for QT prolongation and applicability of results to vulner-
able patients.30 Because of the unpredictable nature of 
the condition, the Drug-induced Arrhythmia Risk Evalua-
tion (DARE) study aimed to improve the understanding 
of the epidemiology of proarrhythmia by establishing a 
cohort of cases of drug-induced arrhythmia reported 
throughout England, to characterise typical patients with 
proarrhythmia and to describe the drugs found to be 
culpable in these cases of proarrhythmia. This manuscript 
is a per-protocol descriptive analysis of risk factors for the 
condition and the contribution of individual drugs to the 
risk of drug-induced arrhythmic events.
MethOds
study design and setting
Cardiologists across England were notified of the study 
by the British Pacing and Electrophysiology Group and 
the British Cardiac Society and asked to recruit patients. 
Study awareness and participation was further promoted 
by project presentation and local interaction across the 
country. Cases of suspected proarrhythmia were referred 
by cardiologists in England between March 2003 and 
July 2011. All consenting cases attended a face-to-face 
interview with a regional study nurse (North, South or 
Midlands regions) between May 2005 and August 2011.
Participants
Cases of proarrhythmia were included if they had 
one or more of the following criteria, all diagnosed as 
secondary to therapeutic drug administration or over-
dose: documented TdP, VF or VT (polymorphic or 
monomorphic, not associated with QT prolongation); 
exacerbation of pre-existing non-sustained arrhythmias 
to sustained; severe prolongation of the QTc interval 
corrected using Bazett’s formula (>500 ms) without symp-
toms; or moderate prolongation of the QTc interval 
(≥450 ms in men or ≥470 ms in women) with a clinical 
history of cardiac syncope.
All cases were reviewed by at least two experienced 
cardiologists, using hospital notes and interview ques-
tionnaire information, to ensure appropriate inclusion of 
cases. Patients with acute ischaemia, ischaemic polymor-
phic VT and structural heart disease (using symptoms, 
history of ischaemia and associated therapy, risk factors or 
ECG, stress test and coronary angiography results) were 
excluded. Case presentation (asymptomatic, syncope, VT, 
VF and/or TdP) and aetiology (QT prolongation-asso-
ciated and non-QT prolongation-associated) were ascer-
tained. Drugs received by the patient were adjudicated for 
culpability in contributing to proarrhythmia according to 
the clinical data, timing of medication and the presenting 
event that prompted referral. Prior reports of associa-
tion with proarrhythmia were also taken into account, 
although drugs thought to contribute to causation but 
without such data were not excluded.
No sample size calculation could be performed for the 
study as, at the time of study initiation, the natural history, 
relative risk and potential risk factors of proarrhythmia 
were largely unknown.
Variables
A proforma questionnaire obtained patients’ self-re-
ported information on age, gender, ethnicity, weight, 
height, smoking status, alcohol consumption, symptoms 
before, during and after the event (including ‘blackout’, 
‘near blackout’, ‘dizziness/light-headedness’ and ‘palpi-
tations’), medication taken before, during and after the 
event (including prescription, over-the-counter/herbal 
and recreational), any medical and cardiovascular history 
(including angina, myocardial infarction, ‘heart failure’, 
‘heart valve problem’, ‘heart rhythm problem’, ‘high 
blood pressure’, hypokalaemia, hypothyroidism, diabetes 
mellitus, ‘stroke’, transient ischaemic attack, ‘liver 
problem’, ‘kidney problem’) and family medical history 
(including ‘sudden death’ and ‘unexplained blackout’). 
History of proarrhythmic events was validated using each 
patient’s hospital notes and an ECG taken at the time of 
the interview. Patient hospital notes, where available, were 
also used to validate drug history (including the drug(s) 
considered to be related to the proarrhythmic event), 
and medical and cardiovascular history for all cases.
Culpable drugs were mapped to the Anatomical Thera-
peutic Chemical classification system. The drugs were then 
classified according to the CredibleMeds register risk of 
causing QT prolongation and/or TdP into the following 
groups: known risk, possible risk, conditional risk and 
no known risk. Drugs are classified as having known risk 
when there is substantial evidence for QT interval prolon-
gation and TdP risk when used according to the label; 
possible risk when there is substantial evidence for QT 
interval prolongation but insufficient evidence of TdP 
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Figure 1 Referrals and cohort accrual.
Figure 2 Geographical distribution of consultant 
cardiologists referring proarrhythmia cases.
risk when used according to the label; and conditional 
risk when there is substantial evidence for QT interval 
prolongation and TdP risk but only under specific condi-
tions (eg, overdose, interaction with another drug). 
Drugs were also classified according to cytochrome (CYP) 
P450 activity (inhibitors and inducers), and potential 
pharmacodynamics interactions were identified using 
the Drug Interaction Checker (Medscape). Potential 
pharmacodynamics interactions were classified into one 
of the following groups: QTc prolongation; cardiotoxic 
(non-QTc prolongation-related but other cardiac effect 
likely, eg, bradycardia or other dysrhythmia); conditional 
(cardiac effect unclear but drug interaction has an impact 
on a proarrhythmic risk factor, eg, potassium levels); 
and other (non-cardiovascular) or no drug interaction.
statistical methods
Statistical analysis involved descriptive statistics, including 
measures of central tendency and dispersion for contin-
uous variables (mean, SD, median, range and percen-
tiles) and frequencies with proportions for categorical 
variables. Results were also stratified according to type 
of arrhythmia (QT prolongation-associated and/or 
non-QT prolongation-associated). All statistical analyses 
were performed using Stata V.12. Radar plots were also 
constructed in order to characterise cases and estimate 
the contribution of individual drugs to risk of proar-
rhythmia. Missing information relating to patients was 
described using a ‘not known’ category.
results
case characteristics
The final overall cohort consisted of 130 cases (figure 1), 
who were referred from a total of 98 consultant cardi-
ologists across England (figure 2). As the majority of 
cases were Caucasian (n=124, 95.4%), the analysis was 
performed on these individuals only. Characteristics of 
the final cohort of Caucasian cases are shown in table 1. 
Cases were 62.9% female with a median age at interview 
of 66 years (IQR 52–73 years). All cases were adults (≥18 
years). Around a third (35.5%) had a family history of 
sudden death. The types of arrhythmia reported in cases 
are shown in table 1. The majority of cases reported TdP, 
VF or cardiac arrest with QT prolongation (n=79, 63.7%), 
of whom 56 (45.2%) presented with TdP, 13 (10.5%) 
presented with VF and 10 (8.1%) presented with TdP 
and VF. However, 23% (n=28) of cases involved VT or VF 
not related to QT prolongation. Median (SD) QTc values 
were 578 (69) ms in QT prolongation-associated cases and 
466.7 (40) ms in non-QT prolongation-associated cases.
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Table 1 Characteristics of cases (n=124)
Characteristics n (% of cases)
Gender
  Female 78 (62.9)
  Male 46 (37.10)
Age at interview (years)
  10–19 2 (1.6)
  20–29 2 (1.6)
  30–39 7 (5.7)
  40–49 15 (12.1)
  50–59 20 (16.1)
  60–69 33 (26.6)
  70–79 37 (29.8)
  80–89 8 (6.5)
  Median (IQR) 66 (52–73)
Smoking status
  Current 13 (10.5)
  Ex-smoker 58 (46.8)
  Never smoked 51 (41.1)
  Not known 2 (1.6)
Alcohol use
  Yes 92 (74.2)
  No 32 (25.8)
Body mass index (kg/m2)
  <18.5 (underweight) 5 (4.0)
  18.5–24.9 (normal) 55 (44.4)
  25–29.9 (overweight) 31 (25.0)
  ≥30 (obese) 33 (26.6)
Family history
  Unexplained syncope 17 (13.7)
  Sudden death 44 (35.5)
Medical history*
  High blood pressure 66 (53.2)
  Hypokalaemia 33 (26.6)
  Hypothyroidism 22 (17.7)
  Angina 26 (21.0)
  Myocardial infarction 27 (21.8)
  Heart failure 17 (13.7)
  Cardiomegaly 21 (16.9)
  Heart value problem 34 (27.4)
  Heart rhythm problem 90 (72.6)
  Stroke 10 (8.1)
  Transient ischaemic attack 11 (8.9)
  Diabetes mellitus 23 (17.7)
  Kidney disease 21 (16.9)
  Liver disease 10 (8.1)
Type of arrhythmia/ECG abnormality
Continued
Characteristics n (% of cases)
QTp associated 95 (76.6)
  TdP, VF, cardiac arrest 79 (63.7)
  QTp >500 ms without symptoms 9 (7.3)
  QTp (≥450 ms in men or ≥470 ms in 
women) with syncope 7 (5.7)
Not associated with QTp 29 (23.4)
  VT/VF 28 (22.6)
  Exacerbation of pre-existing VT only 1 (0.8)
*Self-reported with validation from patient’s hospital notes 
(where available).
QTp, QT interval prolongation; TdP, Torsade de Pointes; VF, 
ventricular fibrillation; VT, ventricular tachycardia.
Table 1 Continued 
culpable drugs
A total of 165 patient drug exposures to 42 drugs deemed 
culpable were identified (table 2, two drugs were unspec-
ified). The most frequently associated drug class was the 
antiarrhythmics, with 70 drug exposures (42.4% of drug 
exposures) in 67 (54.0%) patients. Amiodarone (n=40; 
24.2% of drug exposures; 32.3% of patients), flecainide 
(n=23; 13.9% of drug exposures; 18.6% of patients) and 
sotalol, a beta-blocker with class III properties (n=25; 
15.2% of drug exposures; 20.2% of patients), were the 
most frequently reported single drug causes and known 
to carry a risk of QTc prolongation and/or TdP. Antibi-
otics (eg, erythromycin; n=5, 3.0% of drug exposures; 
4.0% of patients) and antidepressants (eg, citalopram; 
n=7, 4.2% of drug exposures; 5.7% of patients) were also 
implicated.
Of the 42 culpable drugs, 14 (33.3%) drugs carried 
a known risk (120 (72.7%) drug exposures), 8 (19.0%) 
carried a conditional risk (16 (9.7%) drug exposures), 
6 (14.3%) carried a possible risk (7 (4.2%) drug expo-
sures), 1 (2.4%) carried a risk in individuals with cLQTS, 
and 13 (31.0%) carried no known risk of QTc prolonga-
tion and/or TdP (18 (10.9%) drug exposures). The level 
of risk could not be established for two drugs.
Of the 13 culpable drugs carrying no known risk of QTc 
prolongation and/or TdP, 2 are known to contribute to 
bradycardia (timolol and digoxin), 2 are ‘not classified’ 
according to CredibleMeds based on the evidence avail-
able (cetirizine and verapamil) and 1 remains under 
active review (lofexidine).
Multiple drug combinations (table 3) were reported 
in 32 (25.8%) patients. Specifically, 27 (21.8%) patients 
reported two drugs, 2 (1.6%) patients reported three 
drugs, 2 (1.6%) patients reported four drugs and 1 (0.8%) 
patient reported five drugs. Two patients had unspecified 
drug combinations. Of the patients reporting more than 
one drug, 84.4% (27/32) reported using at least one cyto-
chrome P450 inhibitor, with 6 (18.8%) using two or more 
in combination. A single patient reported using a CYP 
inducer. Potential pharmacodynamics interactions within 
group.bmj.com on October 31, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Coughtrie AL, et al. BMJ Open 2017;7:e016627. doi:10.1136/bmjopen-2017-016627
Open Access
Table 2 Drugs culpable in proarrhythmia cases, stratified by risk of QT prolongation and/or Torsades de Pointes
Drug name ATC code Drug type Drug exposures (n) %
Known risk
  Amiodarone C01BD01 Antiarrhythmic 40 24.2
  Sotalol C07AA07 Beta-blocking agent/antiarrhythmic 25 15.2
  Flecainide C01BC04 Antiarrhythmic 23 13.9
  Citalopram N06AB04 Antidepressant 7 4.2
  Erythromycin J01FA01 Antibacterial 5 3.0
  Clarithromycin J01FA09 Antibacterial 4 2.4
  Disopyramide C01BA03 Antiarrhythmic 4 2.4
  Domperidone A03FA03 Propulsive 4 2.4
  Fluconazole J02AC01 Antimycotic 2 1.2
  Thioridazine N05AC02 Antipsychotic 2 1.2
  Ciprofloxacin J01MA02 Antibacterial 1 0.6
  Haloperidol N05AD01 Antipsychotic 1 0.6
  Methadone N07BC02 Drug used in addictive disorders 1 0.6
  Pimozide N05AG02 Antipsychotic 1 0.6
Possible risk
  Venlafaxine N06A×16 Antidepressant 3 1.8
  Antihistamine R06A Antihistamine 1 0.6
  Capecitabine L01BC06 Antimetabolite 1 0.6
  Clomipramine N06AA04 Antidepressant 1 0.6
  Olanzapine N05AH03 Antipsychotic 1 0.6
  Tamoxifen L02BA01 Antioestrogen 1 0.6
Conditional risk
  Furosemide C03CA01 Diuretic 5 3.0
  Amitriptyline N06AA09 Antidepressant 3 1.8
  Bendroflumethiazide C03AA01 Diuretic 2 1.2
  Fluoxetine N06AB03 Antidepressant 2 1.2
  Amisulpride N05AL05 Antipsychotic 1 0.6
  Paroxetine N06AB05 Antidepressant 1 0.6
  Quinine P01BC01 Antimalarial 1 0.6
  Trazodone N06A×05 Antidepressant 1 0.6
Drugs to avoid in cLQTS
  Trimethoprim J01EA01 Antibacterial 1 0.6
No known risk
  Digoxin* C01AA05 Cardiac glycoside 4 2.4
  Propafenone C01BC03 Antiarrhythmic 3 1.8
  Cetirizine† R06AE07 Antihistamine 1 0.6
  Chlorpheniramine R06AB02 Antihistamine 1 0.6
  Dosulepin N06AA16 Antidepressant 1 0.6
  Lofexidine‡ N07BC04 Drug used in addictive disorders 1 0.6
  Loratadine R06A×13 Antihistamine 1 0.6
  Procaine S01HA05 Local anaesthetic 1 0.6
  Theophylline R03DA04 Drug for obstructive airways disease 1 0.6
  Thiazide C03 Diuretic 1 0.6
  Timoptol* C07AA06 Beta-blocking agent 1 0.6
Continued
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Drug name ATC code Drug type Drug exposures (n) %
  Statin C10A Lipid-modifying agent 1 0.6
  Verapamil† C08DA01 Calcium-channel blocker 1 0.6
Unspecified – – 2 1.2
Total – – 165 100.0
*Contributed to bradycardia.
†Not classified—these drugs have been reviewed by CredibleMeds; however, classification could not be performed based on the evidence 
available and there is no indication the drugs are free of risk of QTp/TdP.
‡Under active review for possible risk of QTp/TdP.
ATC, Anatomical Therapeutic Chemical; cLQTS, congenital long QT syndrome; QTp, QT interval prolongation; TdP, Torsades de Pointes.
Table 2 Continued 
patients reporting more than one drug, according to the 
Medscape Drug Interaction Checker, were QTc prolon-
gation (19/32, 59.4%), cardiotoxic (3/32, 9.4%), condi-
tional (1/32, 3.1%) and other (non-cardiovascular; 2/32, 
3.6%) interactions. Seven patients (21.9%) reported a 
drug combination without a potential drug interaction.
types of arrhythmia
Types of proarrhythmia identified within this study 
included QT prolongation-related (n=95, 76.6%) and 
non-QT prolongation-related (n=29, 23.4%), the latter 
more typically associated with QRS prolongation (table 2). 
Stratification according to proarrhythmia type demon-
strated few differences between the characteristics of QT 
prolongation-related and non-QT prolongation-related 
cases of proarrhythmia, with similar frequency of past 
medical conditions within both types (figure 3). Similarly 
drugs deemed culpable in cases of proarrhythmia were 
similar between these types, except for flecainide, which 
was more commonly implicated with non-QT prolon-
gation-related compared with QT prolongation-related 
(figure 4).
dIscussIOn
The DARE study established a cohort of 130 cases of 
clinically validated drug-induced proarrhythmia referred 
from across England. To our knowledge this is the largest 
single study describing a cohort of cases of drug-induced 
arrhythmia. This information can be used in conjunction 
with other methods for evaluating the risk of drug-in-
duced arrhythmias, such as spontaneous reports, health-
care databases and active surveillance studies. An analysis 
of 124 Caucasian cases was undertaken. These Caucasian 
cases were predominantly female (62.9%) and middle-
aged or elderly (median age at interview of 66 years (IQR 
52–73 years)). The majority reported significant past 
cardiac comorbidity including heart rhythm problems 
(72.6%), high blood pressure (53.2%), heart valve prob-
lems (27.4%), angina (21.0%) and myocardial infarction 
(21.8%). This is consistent with data that demonstrate 
arrhythmia or heart failure to be a risk for proarrhythmia.31 
Over a third of cases also had an associated family history 
of sudden death, supporting the potential genetic risk for 
drug-induced arrhythmia.21 Additionally, over a quarter 
of cases presented with hypokalaemia (26.6%). Hypoka-
laemia is associated with QT interval prolongation due to 
increased competitive blockade of IKr, which causes loss 
of function of the hERG (human Ether-a-go-go Related 
Gene) channel.16
Risk factors for proarrhythmia have been studied 
before. For example, one study demonstrated hypoka-
laemia, myocardial infarction, sepsis and heart failure to 
be risk factors for QT prolongation in both drug-induced 
and non-drug-induced hospitalised cases.32 Furthermore, 
a study of 21 patients with drug-induced QT prolonga-
tion from a Greek hospital found hypertension, female 
gender, paroxysmal atrial tachyarrhythmias and old age 
(>60 years) to be common characteristics of patients 
presenting with the condition.33 A study of a group of 
methadone users in Switzerland demonstrated greater 
risk of QT prolongation with hypokalaemia, higher 
methadone dose, altered liver function and use of P450 
cytochrome inhibitors.34 Finally, a study of psychiatric 
patients with drug-induced LQTS showed hypokalaemia, 
abnormal T wave as well as hepatitis C and HIV infection 
to increase the risk of LQTS in this population.35
In our study amiodarone, sotalol and flecainide were the 
most common culpable drugs as was the antiarrhythmic 
drug group as a whole (42.2% of drug exposures). Their 
high prevalence may be due to the relative high potency 
of cardiac current blockade and/or reflect that cardiolo-
gists were the main referral source of cases. For example 
clinical trials of patients with ventricular and supraventric-
ular arrhythmias treated with sotalol have shown a 4.3% 
prevalence of proarrhythmia.36 While class Ia, Ic and III 
antiarrhythmics carry a known risk of QT prolongation 
and/or TdP and can be potent IKr blockers, amiodarone 
is often thought of as a rare cause of TdP.37 Its importance 
in our cohort may be due to its relatively frequent use as 
an antiarrhythmic agent and/or that those most vulner-
able to aLQTS (ie, elderly women with cardiac comor-
bidity) are more likely to receive amiodarone than other 
antiarrhythmics due to its perceived lower proarrhythmic 
risk. This is therefore an important warning to clinicians. 
Proarrhythmia unrelated to QT prolongation was most 
commonly observed in users of flecainide, recognised to 
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Figure 3 Characteristics of QTp-related and non-QTp-related cases of proarrhythmia. FH, family history; QTp, QT interval 
prolongation; TIA, transient ischaemic attack.
Figure 4 Drugs (Anatomical Therapeutic Chemical codes) culpable in cases of proarrhythmia. QTp, QT interval prolongation.
result from conduction slowing, causing QRS duration 
prolongation.38 Amiodarone was also frequently reported 
to be associated with LQTS and TdP in a recent active 
surveillance study of 58 cases in Germany, a study that 
showed similar results to DARE, including the identifica-
tion of hypokalaemia as a risk factor for LQTS and TdP.39
Nearly three-quarters of the culpable drug exposures were 
caused by drugs with known risk of QT prolongation and/
or TdP, including antibiotics and antidepressants. However, 
13 (31.0%) different drugs were diagnosed as culpable in 
proarrhythmia but not recognised as having such a risk 
according to the CredibleMeds register. Two are known 
to contribute to bradycardia (a risk for proarrhythmia), 
two are ‘not classified’ according to CredibleMeds based 
on the evidence available and one remains under active 
review (lofexidine). Drug combinations were also culpable 
in a quarter of cases, with up to five drugs being reported 
in combination. Of these drug combinations by far the 
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majority, 84.4% (27/32), included at least one cytochrome 
P450 inhibitor. Drug combinations of antipsychotics and 
antidepressants have also previously been shown to increase 
the risk of QT interval prolongation when compared with 
antipsychotics alone.40 Concurrent use of more than one 
QT-prolonging drug or concurrent use with a drug that alters 
the pharmacokinetic profile of the drug is an important 
risk factor for adverse outcomes. On the other hand, other 
studies have shown no increased risk of QT interval prolon-
gation with the use of multiple QT-prolonging drug combi-
nations compared with single drugs.32 Furthermore, drugs 
with no known risk of QTc prolongation when used alone 
may result in prolongation of the QTc interval when used 
in combination. For example, ceftriaxone and lansoprazole 
were identified as having a risk of QTc prolongation when 
used together using electronic healthcare records and in 
vitro methodology.41 Drug interactions were also reported 
to represent a high proportion of cases of drug-induced 
TdP within a Belgium study using the EudraVigilance data-
base (18 of 31 cases).42
Limitations of the DARE study include the inability to 
enrol patients who may have suffered from sudden death 
as a result of drug-induced arrhythmia; for ethical reasons 
only live patients could be included. Furthermore, as all 
referrals came from cardiologists, this may have resulted 
in selection bias and underestimation of the prevalence 
of drug-induced arrhythmia from non-cardiac drugs. The 
level of underestimation due to sudden death or cardiolo-
gist referral is difficult to quantify. Determining the cause of 
death in patients with sudden cardiac death is challenging, 
with ion channelopathies potentially accounting for 40% of 
cases of sudden arrhythmic death syndrome, being unde-
tectable after a patient has died.43 A comparison with spon-
taneous reports of drug-induced arrhythmia might provide 
information on the level of underestimation of the preva-
lence of drug-induced arrhythmia from non-cardiac drugs; 
however, under-reporting of severe adverse drug reactions 
is known to be high, at approximately 80%.44 In addition, 
patient answers to questionnaires may have been subject 
to recall bias and some of the patient information could 
not be validated from patient records. Finally, differences 
in ethnicity could not be investigated in this group as there 
were too few cases of non-Caucasian ethnic origin. Ethnic 
differences have been shown to affect the risk of QT prolon-
gation due to polymorphisms in cardiac ion channels.45 
With a larger number of cases, ethnicity differences could 
be further investigated. It would also be desirable to esti-
mate the incidence of proarrhythmia within the UK popu-
lation, as has been done for a similar study.39 Future work 
might also involve an investigation of specific drug types 
and how exposure duration and patterns of usage might 
affect the risk of proarrhythmias.
cOnclusIOns
Increased awareness in the past decade of the public 
health risk of QT-prolonging drugs has resulted in 
the regulatory authorities producing guidelines for 
studying the potential for QT prolongation in premar-
keting development and the adoption of risk-minimis-
ation measures.29 However, due to rarity and diagnostic 
difficulties, the lack of reported TdP cases in premar-
keting or postmarketing safety monitoring is a chal-
lenge for drug safety.46 To date, linked epidemiological 
and pharmacogenetic data on proarrhythmic events 
have been lacking. As such, the DARE study has allowed 
the development of a cohort of cases that provide 
crucial safety information, as well as underlying clin-
ical and genetic data.18 47 48 DARE has provided infor-
mation that confirms risk factors for proarrhythmia, 
including patient comorbidities and use of drugs with 
known QTc prolongation risk. However, the study has 
also identified higher frequency of amiodarone as well 
as reports of drugs with no known QTc prolongation 
risk.
Caution is necessary when prescribing class I and III 
antiarrhythmic drugs. These include amiodarone given 
its frequent use in clinical practice. The prescriber needs 
to be aware of a patient’s concomitant medications and 
comorbidities, especially middle-aged to elderly women 
with cardiovascular disease and/or a family history of 
sudden death, as well as the likelihood of hypokalaemia. 
Furthermore prescribers must be aware of the contribu-
tion of non-cardiac drugs to the burden of drug-induced 
arrhythmias,49 with approximately 3% of prescriptions 
in the UK representing non-cardiac drugs with warnings 
for arrhythmic potential.50 Our findings reinforce the 
need for safer prescribing of proarrhythmic drugs in 
clinical practice.
Acknowledgements The authors would like to thank the cardiologists who 
referred patients to the study, Pauline Telfer for her administrative assistance and 
Linda Robinson for data collection. The authors also thank the Steering Committee, 
the British Pacing and Electrophysiology Group (BPEG), now British Heart Rhythm 
Society (BHRS), and the British Cardiac Society (BCS), which were instrumental 
in the recruitment of patients. The authors also thank Ed Tong for his statistical 
support.
contributors AJC, SAWS, ERB and DL designed the study. VM was responsible for 
data acquisition. ALC, DL and ERB performed the analyses. ALC, DL, VM, ERB, AJC 
and SAWS interpreted the findings. ALC, VM, ERB and DL wrote the first draft of 
the manuscript and revised subsequent versions. The other authors provided input, 
expertise and critical review of the paper. All authors read and approved the final 
version of the paper. AJC and SAWS are the guarantors.
Funding The DARE study was funded by the British Heart Foundation under special 
project grant SP/02/001.
competing interests ERB was supported by grants from the international 
Serious Adverse Events Consortium during the conduct of the study. SAWS reports 
personal fees from ICON, Shire Pharmaceuticals, ONO Pharmaceuticals, Intermune 
Pharma and IPSEN outside of the submitted work. AJC reports personal fees 
from Mitsubishi, Laguna, Bayer, Biotronik, Richmond Pharmacology, Boehringer 
Ingelheim, Daiichi, Menarini, Novartis, St Jude Medical, Bristol-Myers-Squibb, 
Pfizer, Medtronic, Thrombosis Research Institute, Servier, Boston Scientific, Eli Lilly 
and Company, and organisational (non-commercial) fees from the European Heart 
Rhythm Association outside the submitted work.
ethics approval Ethical approval was gained from the London Multicentre 
Research Ethics Committee (MREC), reference number MREC/02/2/73.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement Additional data available on request by emailing  abigail. 
coughtrie@ dsru. org.
group.bmj.com on October 31, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
10 Coughtrie AL, et al. BMJ Open 2017;7:e016627. doi:10.1136/bmjopen-2017-016627
Open Access 
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerences
 1. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-
prolonging drugs and the risk of sudden cardiac death. Eur Heart J 
2005;26:2007–12.
 2. Ben-David J, Zipes DP. Torsades de pointes and proarrhythmia. 
Lancet 1993;341:1578–82.
 3. Brugada P, Wellens HJ. Arrhythmogenesis of antiarrhythmic drugs. 
Am J Cardiol 1988;61:1108–11.
 4. Gonzalez CD, de Sereday M, Sinay I, et al. Endocrine therapies and 
QTc prolongation. Curr Drug Saf 2010;5:79–84.
 5. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation 
in cirrhosis: prevalence, relationship with severity, and etiology 
of the disease and possible pathogenetic factors. Hepatology 
1998;27:28–34.
 6. Sani MU, Okeahialam BN. QTc interval prolongation in patients with 
HIV and AIDS. J Natl Med Assoc 2005;97:1657–61.
 7. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an 
emerging role for inflammation and immunity. Front Cardiovasc Med 
2015;2:26.
 8. Yue Y, Castrichini M, Srivastava U, et al. Pathogenesis of the 
novel autoimmune-associated long-QT syndrome. Circulation 
2015;132:230–40.
 9. Weissler-Snir A, Gollob MH, Chauhan V, et al. Evaluation of 
prolonged QT interval: structural heart disease mimicking long QT 
syndrome. Pacing Clin Electrophysiol 2017;40:417–24.
 10. Bellet S. The electrocardiogram in electrolyte imbalance.  
AMA Arch Intern Med 1955;96:618–38.
 11. Takimoto Y, Yoshiuchi K, Kumano H, et al. QT interval and 
QT dispersion in eating disorders. Psychother Psychosom 
2004;73:324–8.
 12. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic 
drugs that prolong the QT interval or induce torsade de pointes: an 
overview. Drug Saf 2002;25:263–86.
 13. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval 
prolongation: mechanisms and clinical management.  
Ther Adv Drug Saf 2012;3:241–53.
 14. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT 
prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: 
clinical and regulatory implications. report on a policy conference 
of the european society of cardiology. Cardiovascular research 
2000;47:219–33.
 15. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: 
the long-short initiating sequence and other clinical features: 
observations in 32 patients. J am coll cardiol 1983;2:806–17.
 16. Numaguchi H, Johnson JP, Petersen CI, et al. A sensitive mechanism 
for cation modulation of potassium current. Nat Neurosci 
2000;3:429–30.
 17. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed 
rectifier K+ current. Differential sensitivity to block by class III 
antiarrhythmic agents. J Gen Physiol 1990;96:195–215.
 18. Jamshidi Y, Nolte IM, Dalageorgou C, et al. Common variation in the 
NOS1AP gene is associated with drug-induced QT prolongation and 
ventricular arrhythmia. J Am Coll Cardiol 2012;60:841–50.
 19. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT 
syndrome associated with a subclinical SCN5A mutation. Circulation 
2002;106:1269–74.
 20. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of 
KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long 
QT syndrome patients. J Mol Med 2004;82:182–8.
 21. Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic 
prescribing? Eur Heart J 2013;34:89–95.
 22. Makkar RR, et al. Female gender as a risk factor for torsades 
de pointes associated with cardiovascular drugs. JAMA 
1993;270:2590–7.
 23. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de 
pointes. Heart 2003;89:1363–72.
 24. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of 
torsade de pointes with d,l-sotalol. Circulation 1996;94:2535–41.
 25. Khongphatthanayothin A, Lane J, Thomas D, et al. Effects of 
cisapride on QT interval in children. J Pediatr 1998;133:51–6.
 26. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black 
box warnings and withdrawals for prescription medications. JAMA 
2002;287:2215–20.
 27. Pratt CM, Hertz RP, Ellis BE, et al. Risk of developing life-threatening 
ventricular arrhythmia associated with tefenadine in comparison with 
over-the-counter antihistamines, ibuprofen and clemastine.  
Am J Cardiol 1994;73:346–52.
 28. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports 
of QT prolongation and ventricular arrhythmia in association with 
cisapride and Food and Drug Administration regulatory actions.  
Am J Gastroenterol 2001;96:1698–703.
 29. ICH. Harmonized Tripartite Guideline E14: The Clinical Evaluation of 
QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-
antiarrhythmic Drugs. 2005.
 30. Rock EP, Finkle J, Fingert HJ, et al. Assessing proarrhythmic 
potential of drugs when optimal studies are infeasible. Am Heart J 
2009;157:827–36.
 31. Tisdale JE, Patel R, Webb CR, et al. Electro physiologic and 
proarrhythmic effects of intravenous inotropic agents. Prog 
Cardiovasc Dis 1995;38:167–80.
 32. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation 
of a risk score to predict QT interval prolongation in hospitalized 
patients. Circ Cardiovasc Qual Outcomes 2013;6:479–87.
 33. Letsas KP, Efremidis M, Kounas SP, et al. Clinical characteristics 
of patients with drug-induced QT interval prolongation and 
torsade de pointes: identification of risk factors. Clin Res Cardiol 
2009;98:208–12.
 34. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT 
syndrome in injection drug users receiving methadone: high 
frequency in hospitalized patients and risk factors. Arch Intern Med 
2006;166:1280–7.
 35. Girardin FR, Gex-Fabry M, Berney P, et al. Drug-induced long 
QT in adult psychiatric inpatients: the 5-year cross-sectional 
ECG Screening Outcome in Psychiatry study. Am J Psychiatry 
2013;170:1468–76.
 36. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol 
in patients with arrhythmias. Am J Cardiol 1990;65:74–81.
 37. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated 
proarrhythmic effects. A review with special reference to torsade de 
pointes tachycardia. Ann Intern Med 1994;121:529–35.
 38. Nathan AW, Hellestrand KJ, Bexton RS, et al. The proarrhythmic 
effects of flecainide. Drugs 1985;29(Suppl 4):45–53.
 39. Sarganas G, Garbe E, Klimpel A, et al. Epidemiology of symptomatic 
drug-induced long QT syndrome and torsade de pointes in germany. 
Europace 2014;16:101–8.
 40. Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related 
to psychoactive drug treatment: a comparison of monotherapy 
versus polytherapy. Ann Gen Psychiatry 2005;4:1.
 41. Lorberbaum T, Sampson KJ, Chang JB, et al. Coupling data mining 
and laboratory experiments to discover drug interactions causing QT 
prolongation. J Am Coll Cardiol 2016;68:1756–64.
 42. Vandael E, Vandenberk B, Vandenberghe J, et al. Cases of drug-
induced torsade de pointes: a review of belgian cases in the 
eudravigilance database. Acta Clin Belg 2017:1–6.
 43. Behr ER. Inherited heart conditions: Sudden arrhythmic death 
syndrome. 2009. https://www. bhf. org. uk/-/ media/ files/ publications/ 
heart- conditions/ m111a- life- with- sudden- arrhythmic- death- 
syndrome. pdf.
 44. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a 
systematic review. Drug Saf 2006;29:385–96.
 45. Ackerman MJ, Tester DJ, Jones GS, et al. Ethnic differences 
in cardiac potassium channel variants: implications for genetic 
susceptibility to sudden cardiac death and genetic testing 
for congenital long QT syndrome. Mayo clinic proceedings 
2003;78:1479–87.
 46. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced 
torsades de pointes and implications for drug development. J 
Cardiovasc Electrophysiol 2004;15:475–95.
 47. Behr ER, Ritchie MD, Tanaka T, et al. Genome wide analysis of drug-
induced torsades de pointes: lack of common variants with large 
effect sizes. PLoS One 2013;8:e78511.
 48. Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene 
survey identifies the KCNE1 D85N polymorphism as a possible 
modulator of drug-induced torsades de pointes. Circ Cardiovasc 
Genet 2012;5:91–9.
 49. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac 
drugs. BMJ 2000;320:1158–9.
 50. De Ponti F, Poluzzi E, Montanaro N, et al. QTc and psychotropic 
drugs. Lancet 2000;356:75–6.
group.bmj.com on October 31, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
cohort
arrhythmia risk: results from the DARE study 
Drugs and life-threatening ventricular
John Camm and Saad A W Shakir
Abigail L Coughtrie, Elijah R Behr, Deborah Layton, Vanessa Marshall, A
doi: 10.1136/bmjopen-2017-016627
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/10/e016627
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/7/10/e016627
This article cites 47 articles, 11 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (2184)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 31, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
